HS
HighVista Strategies Portfolio holdings
AUM
$272M
This Quarter Return
+3.78%
1 Year Return
+24.34%
3 Year Return
+176.43%
5 Year Return
+271.23%
10 Year Return
+682.63%
AUM
$274M
AUM Growth
+$274M
(-2.4%)
Cap. Flow
+$1.08M
Cap. Flow
% of AUM
0.39%
Top 10 Holdings %
Top 10 Hldgs %
29.37%
Holding
164
New
33
Increased
27
Reduced
41
Closed
27
Top Buys
| 1 |
HCP
HashiCorp, Inc. Class A Common Stock
HCP
|
$4.39M |
| 2 |
CTLT
CATALENT, INC.
CTLT
|
$4.25M |
| 3 |
ETRN
Equitrans Midstream Corporation Common Stock
ETRN
|
$4.02M |
| 4 |
Teva Pharmaceuticals
TEVA
|
$2.22M |
| 5 |
Salesforce
CRM
|
$2.19M |
Top Sells
| 1 |
SP
SP Plus Corporation
SP
|
$4.12M |
| 2 |
Orthofix Medical
OFIX
|
$2.44M |
| 3 |
Nuvalent
NUVL
|
$2.38M |
| 4 |
Immunocore
IMCR
|
$2.26M |
| 5 |
IDEAYA Biosciences
IDYA
|
$2.05M |
Sector Composition
| 1 | Healthcare | 43.71% |
| 2 | Technology | 17% |
| 3 | Consumer Discretionary | 6.54% |
| 4 | Energy | 4.11% |
| 5 | Consumer Staples | 3.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
101
Terns Pharmaceuticals
TERN
$651M
| $1.01M | 0.37% |
148,200
| – | – |
|
102
Janux Therapeutics
JANX
$1.38B
| $977K | 0.36% |
+23,332
| New | +$977K |
|
103
Immatics
IMTX
$662M
| $904K | 0.33% |
+77,821
| New | +$904K |
|
104
Geron
GERN
$893M
| $762K | 0.28% |
179,799
-60,435
| -25% | -$256K |
|
105
CRH
CRH
$75.1B
| $757K | 0.28% |
10,100
-1,100
| -10% | -$82.5K |
|
106
Protagonist Therapeutics
PTGX
$3.62B
| $736K | 0.27% |
21,229
| – | – |
|
107
Bilibili
BILI
$9.2B
| $723K | 0.26% |
46,857
-41,000
| -47% | -$633K |
|
108
Madrigal Pharmaceuticals
MDGL
$9.7B
| $710K | 0.26% |
2,534
| – | – |
|
109
Mirum Pharmaceuticals
MIRM
$3.75B
| $691K | 0.25% |
20,208
| – | – |
|
|
ABVX
110
Abivax
ABVX
$6.32B
| $655K | 0.24% |
49,509
-8,253
| -14% | -$109K |
|
111
Huazhu Hotels Group
HTHT
$11.2B
| $634K | 0.23% |
19,029
-6,900
| -27% | -$230K |
|
112
Alnylam Pharmaceuticals
ALNY
$58.6B
| $632K | 0.23% |
+2,602
| New | +$632K |
|
113
Ascendis Pharma
ASND
$12.1B
| $617K | 0.23% |
4,527
| – | – |
|
114
Rhythm Pharmaceuticals
RYTM
$6.75B
| $590K | 0.22% |
14,362
| – | – |
|
115
Trip.com Group
TCOM
$46.6B
| $553K | 0.2% |
11,756
-873
| -7% | -$41K |
|
116
JD.com
JD
$44.2B
| $496K | 0.18% |
19,183
-43,282
| -69% | -$1.12M |
|
|
VRNA
117
Verona Pharma
VRNA
$9.18B
| $469K | 0.17% |
32,449
| – | – |
|
118
United Therapeutics
UTHR
$17.7B
| $449K | 0.16% |
+1,409
| New | +$449K |
|
119
Ocular Therapeutix
OCUL
$2.25B
| $423K | 0.15% |
+61,859
| New | +$423K |
|
120
Acadia Pharmaceuticals
ACAD
$4.34B
| $421K | 0.15% |
+25,878
| New | +$421K |
|
121
Natera
NTRA
$23B
| $386K | 0.14% |
+3,568
| New | +$386K |
|
122
KalVista Pharmaceuticals
KALV
$713M
| $375K | 0.14% |
31,873
| – | – |
|
123
Sarepta Therapeutics
SRPT
$1.98B
| $374K | 0.14% |
+2,364
| New | +$374K |
|
124
Baidu
BIDU
$33.1B
| $362K | 0.13% |
4,186
-1,300
| -24% | -$112K |
|
|
TSVT
125
DELISTED
2seventy bio
TSVT
| $360K | 0.13% |
93,500
| – | – |
|